Karen Lindorff-Larsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karen Lindorff-Larsen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Henrik Højgaard Rasmussen
Center for Nutrition and Intestinal Failure, Aalborg University Hospital, Aalborg University, 9220 Aalborg, Denmark; The Dietitians and Nutritional Research Unit, EATEN, Copenhagen University Hospital-Herlev and Gentofte, 2100 Copenhagen, Denmark
2 shared publications - Erik Berg Schmidt
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
1 shared publication - Lone Schmidt Sorensen
Department of Surgical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication - Lotte Boa Skadhauge
Centre for Nutrition and Bowel Disease, Department of Gastroenterology, Aalborg University Hospital and Aalborg University, Denmark
1 shared publication - Martin Mortensen
Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK
1 shared publication - Mette Holst
Centre for Nutrition and Intestinal Failure, Department of Gastroenterology Aalborg University Hospital Aalborg Denmark
1 shared publication
Latest Publications
- 1 April 2015
- Published by Elsevier in Clinical Nutrition
- Vol. 34 (2) , 315-322
Multi-modal intervention improved oral intake in hospitalized patients. A one year follow-up study
- 1 April 2015
- Published by Elsevier in Clinical Nutrition
- Vol. 34 (2) , 315-322
Multi-modal intervention improved oral intake in hospitalized patients. A one year follow-up study
- Open Access
Effects of Perioperative Supplementation with Omega-3 Fatty Acids on Leukotriene B4 and Leukotriene B5 Production by Stimulated Neutrophils in Patients with Colorectal Cancer: A Randomized, Placebo-Controlled Intervention Trial
Omega-3 fatty acids (n-3 FA) may have beneficial clinical and immune-modulating effects in surgical patients. In a randomized, double-blind, prospective, placebo-controlled trial, 148 patients referred for elective colorectal cancer surgery received an n-3 FA-enriched oral nutritional supplement (ONS) providing 2.0 g of eicosapentaenoic acid (EPA) and 1.0 g of docosahexaenoic acid (DHA) per day or a standard ONS for seven days before surgery. On the day of operation, there was a significant increase in the production of leukotriene B5 (LTB5) (p < 0.01) and 5-hydroxyeicosapentaenoic acid (5-HEPE) (p < 0.01), a significant decrease in the production of leukotriene B4 (LTB4) (p < 0.01) and a trend for a decrease in the production of 5-hydroxyeicosatetraenoic acid (5-HETE) (p < 0.1) from stimulated neutrophils in the active group compared with controls. There was no association between LTB4 values and postoperative complications. In conclusion, oral n-3 FA exerts anti-inflammatory effects in surgical patients, without reducing the risk of postoperative complications.
Open AccessEffects of Perioperative Supplementation with Omega-3 Fatty Acids on Leukotriene B4 and Leukotriene B5 Production by Stimulated Neutrophils in Patients with Colorectal Cancer: A Randomized, Placebo-Controlled Intervention Trial
Omega-3 fatty acids (n-3 FA) may have beneficial clinical and immune-modulating effects in surgical patients. In a randomized, double-blind, prospective, placebo-controlled trial, 148 patients referred for elective colorectal cancer surgery received an n-3 FA-enriched oral nutritional supplement (ONS) providing 2.0 g of eicosapentaenoic acid (EPA) and 1.0 g of docosahexaenoic acid (DHA) per day or a standard ONS for seven days before surgery. On the day of operation, there was a significant increase in the production of leukotriene B5 (LTB5) (p < 0.01) and 5-hydroxyeicosapentaenoic acid (5-HEPE) (p < 0.01), a significant decrease in the production of leukotriene B4 (LTB4) (p < 0.01) and a trend for a decrease in the production of 5-hydroxyeicosatetraenoic acid (5-HETE) (p < 0.1) from stimulated neutrophils in the active group compared with controls. There was no association between LTB4 values and postoperative complications. In conclusion, oral n-3 FA exerts anti-inflammatory effects in surgical patients, without reducing the risk of postoperative complications.